{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:01:26Z","timestamp":1781373686738,"version":"3.54.1"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To share important highlights on the management of anaphylaxis from the latest 2023 practice parameter.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The 2023 Allergy Immunology Joint Task Force on Practice Parameters (JTFPP) anaphylaxis practice parameter provides updated anaphylaxis guidance. Criteria for the diagnosis of anaphylaxis are reviewed. The parameter highlights that while anaphylaxis is not more severe in younger children, age-specific symptoms can vary. Activation of emergency medical services may <jats:italic toggle=\"yes\">not<\/jats:italic> be required in patients who experience prompt resolution of symptoms following epinephrine use and caregivers are comfortable with observation. For children weighing &lt;15\u200akg, the anaphylaxis parameter suggests the clinician may prescribe either the 0.1\u200amg or the 0.15\u200amg epinephrine autoinjector, with the 0.3\u200amg autoinjector prescribed for those weighing 25\u200akg or greater. In patients with heart disease, discontinuing or changing beta blockers and\/or angiotensin converting enzyme inhibitors may pose a larger risk for worsened cardiovascular disease compared with risk for severe anaphylaxis with medication continuation. Furthermore, in patients with a history of perioperative anaphylaxis, shared decision-making based on diagnostic testing and clinical history is recommended prior to repeat anesthesia use. Beyond the recent parameter update, novel contemporary therapies can decrease risk of community anaphylaxis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The 2023 JTFPP Anaphylaxis Guidelines offer up-to-date guidance for the diagnosis and management of anaphylaxis in infants, children, and adults.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001397","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:40:59Z","timestamp":1725982859000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pearls for practice from the 2023 joint task force anaphylaxis practice parameter"],"prefix":"10.1097","volume":"37","author":[{"given":"Chaitanya","family":"Maddukuri","sequence":"first","affiliation":[{"name":"Cleveland Clinic Southpointe, Department of Medicine, Cleveland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navya","family":"Kartha","sequence":"additional","affiliation":[{"name":"Akron Children's Hospital, Department of Pediatrics, Akron, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Conway","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus S.","family":"Shaker","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth, Departments of Medicine and Pediatrics, Hanover"},{"name":"Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"R1-20241219","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R2-20241219","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20241219","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jaip.2022.04.040","article-title":"Acute at-home management of anaphylaxis: 911: what is the emergency?","volume":"10","author":"Casale","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R4-20241219","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jaip.2016.05.005","article-title":"The emperor has no symptoms: the risks of a blanket approach to using epinephrine autoinjectors for all allergic reactions","volume":"4","author":"Turner","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R5-20241219","doi-asserted-by":"crossref","DOI":"10.1097\/MOP.0000000000001381","article-title":"Pearls for practice from the 2023 allergy immunology joint task force on practice parameters GRADE and institute of medicine based atopic dermatitis guidelines","author":"Conway","year":"2024","journal-title":"Curr Opin Pediatr"},{"key":"R6-20241219","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Panel AAJADG","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R7-20241219","article-title":"Patient-centered practice guidelines: GRADEing evidence to incorporate certainty, balance between benefits and harms, equity, feasibility, and cost-effectiveness","volume":"S2213-2198","author":"Stephen","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R8-20241219","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2021.01.003","article-title":"Severity grading system for acute allergic reactions: a multidisciplinary Delphi study","volume":"148","author":"Dribin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R9-20241219","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jaip.2018.02.026","article-title":"Epinephrine in severe allergic reactions: the european anaphylaxis register","volume":"6","author":"Grabenhenrich","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R10-20241219","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/EDE.0000000000001330","article-title":"Identification and validation of anaphylaxis using electronic health data in a population-based setting","volume":"32","author":"Bann","year":"2021","journal-title":"Epidemiology"},{"key":"R11-20241219","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J Adv Nurs"},{"key":"R13-20241219","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.anai.2023.05.033","article-title":"Innovations in the treatment of anaphylaxis: a review of recent data","volume":"131","author":"Lieberman","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R14-20241219","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1016\/j.jaip.2021.05.038","article-title":"The revenge of unintended consequences of anaphylaxis-risk overdiagnosis: how far we have come and how far we have to go","volume":"9","author":"Abrams","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R15-20241219","first-page":"429","article-title":"Underdiagnosis of anaphylaxis in the emergency department: misdiagnosed or miscoded?","volume":"19","author":"Hocagil","year":"2013","journal-title":"Hong Kong Med J"},{"key":"R16-20241219","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jaip.2016.06.003","article-title":"Prospective validation of the NIAID\/FAAN criteria for emergency department diagnosis of anaphylaxis","volume":"4","author":"Loprinzi Brauer","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R17-20241219","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"R19-20241219","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R20-20241219","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/all.13226","article-title":"Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective","volume":"72","author":"Baretto","year":"2017","journal-title":"Allergy"},{"key":"R21-20241219","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R22-20241219","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"R23-20241219","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"R24-20241219","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R25-20241219","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R26-20241219","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"R27-20241219","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaip.2019.11.003","article-title":"Diagnostic challenges in anaphylaxis","volume":"8","author":"Lieberman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R28-20241219","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"R29-20241219","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20241219","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R31-20241219","doi-asserted-by":"crossref","first-page":"e13743","DOI":"10.1111\/pai.13743","article-title":"The burden of food allergy on children and teens: a systematic review","volume":"33","author":"Golding","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"R32-20241219","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaip.2020.09.018","article-title":"Food-induced anaphylaxis in infants: can new evidence assist with implementation of food allergy prevention and treatment?","volume":"9","author":"Tsuang","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R33-20241219","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: mortality rate and risk factors","volume":"5","author":"Turner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R34-20241219","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaip.2020.11.002","article-title":"A consensus approach to the primary prevention of food allergy through nutrition: guidance from the American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma, and Immunology; and the Canadian Society for Allergy and Clinical Immunology","volume":"9","author":"Fleischer","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R35-20241219","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaci.2019.07.032","article-title":"Earlier ingestion of peanut after changes to infant feeding guidelines: the EarlyNuts study","volume":"144","author":"Soriano","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R36-20241219","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jpeds.2010.10.017","article-title":"Age-related differences in the clinical presentation of food-induced anaphylaxis","volume":"158","author":"Rudders","year":"2011","journal-title":"J Pediatr"},{"key":"R37-20241219","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.anai.2018.05.025","article-title":"Food-induced anaphylaxis in infants and children","volume":"121","author":"Samady","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R38-20241219","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jaip.2018.10.052","article-title":"Guiding principles for the recognition, diagnosis, and management of infants with anaphylaxis: an expert panel consensus","volume":"7","author":"Greenhawt","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R39-20241219","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jaci.2021.01.034","article-title":"Prevention and management of allergic reactions to food in child care centers and schools: practice guidelines","volume":"147","author":"Waserman","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R42-20241219","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jaci.2017.01.040","article-title":"Impact of school peanut-free policies on epinephrine administration","volume":"140","author":"Bartnikas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R43-20241219","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaip.2017.08.013","article-title":"Quality of life for parents of children with food allergy in peanut-restricted versus peanut-free schools in the United States and Canada","volume":"6","author":"Patel","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R44-20241219","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jaip.2020.12.018","article-title":"Characteristics of food allergic reactions in United States restaurants","volume":"9","author":"Oriel","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R45-20241219","article-title":"Allergic diseases and mental health","volume":"S2213-2198","author":"Conway","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R46-20241219","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.anai.2020.01.029","article-title":"Engaging patient partners in state-of-the-art allergy care: finding balance when discussing risk","volume":"125","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R47-20241219","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children:a randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R48-20241219","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jaci.2024.02.019","article-title":"Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent","volume":"153","author":"Mack","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R49-20241219","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/cea.14225","article-title":"Information needs of patients considering oral immunotherapy for food allergy","volume":"52","author":"Mack","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"R50-20241219","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1056\/NEJMc2404288","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"Reply N Engl J Med"},{"key":"R51-20241219","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"R52-20241219","article-title":"The cost-effectiveness of omalizumab for treatment of food allergy","volume":"S2213-2198","author":"Shaker","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R53-20241219","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.jaip.2022.05.040","article-title":"The case for prompt salvage infant peanut oral immunotherapy following failed primary prevention","volume":"10","author":"Chua","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R54-20241219","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jaip.2021.12.009","article-title":"Real-world peanut OIT in infants may be safer than noninfant preschool OIT and equally effective","volume":"10","author":"Soller","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R55-20241219","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamapediatrics.2018.4275","article-title":"Analysis of value-based costs of undesignated school stock epinephrine policies for peanut anaphylaxis","volume":"173","author":"Shaker","year":"2019","journal-title":"JAMA Pediatr"},{"key":"R56-20241219","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jaip.2018.04.036","article-title":"The health and economic outcomes of peanut allergy management practices","volume":"6","author":"Shaker","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R57-20241219","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.waojou.2023.100753","article-title":"WAO consensus on DEfinition of Food Allergy SEverity (DEFASE)","volume":"16","author":"Arasi","year":"2023","journal-title":"World Allergy Organ J"},{"key":"R58-20241219","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jaip.2021.01.007","article-title":"A cost-effectiveness analysis of epinephrine autoinjector risk stratification for patients with food allergy-one epinephrine autoinjector or two?","volume":"9","author":"Shaker","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R59-20241219","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.anai.2018.06.035","article-title":"An economic evaluation of immediate vs nonimmediate activation of emergency medical services after epinephrine use for peanut-induced anaphylaxis","volume":"122","author":"Shaker","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R60-20241219","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaci.2014.09.004","article-title":"Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming","volume":"135","author":"Nassiri","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R61-20241219","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaip.2018.10.042","article-title":"Relationship between anaphylaxis and use of beta-blockers and angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis of observational studies","volume":"7","author":"Tejedor-Alonso","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R62-20241219","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaci.2004.11.012","article-title":"Use of beta-blockers during immunotherapy for Hymenoptera venom allergy","volume":"115","author":"Muller","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R63-20241219","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2004.02.043","article-title":"Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis","volume":"113","author":"TenBrook","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R64-20241219","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaip.2014.11.005","article-title":"Antibiotics are an important identifiable cause of perioperative anaphylaxis in the United States","volume":"3","author":"Gonzalez-Estrada","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R65-20241219","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00000542-200309000-00007","article-title":"Groupe d\u2019Etudes des Reactions Anaphylactoides P. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999\u20132000","volume":"99","author":"Mertes","year":"2003","journal-title":"Anesthesiology"},{"key":"R66-20241219","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0091-6749(97)70222-7","article-title":"Timing of venom skin tests and IgE determinations after insect sting anaphylaxis","volume":"100","author":"Goldberg","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"R67-20241219","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/jclinpath-2019-206157","article-title":"Empty mast cell syndrome: fallacy or fact?","volume":"73","author":"Mohamed","year":"2020","journal-title":"J Clin Pathol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T14:06:26Z","timestamp":1734617186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001397","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}